Actuate Therapeutics (ACTU) Competitors $8.02 -0.11 (-1.35%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends ACTU vs. TECX, NGNE, ANAB, EXAI, AVXL, CRMD, NUVB, QTTB, CRVS, and SLRNShould you be buying Actuate Therapeutics stock or one of its competitors? The main competitors of Actuate Therapeutics include Tectonic Therapeutic (TECX), Neurogene (NGNE), AnaptysBio (ANAB), Exscientia (EXAI), Anavex Life Sciences (AVXL), CorMedix (CRMD), Nuvation Bio (NUVB), Q32 Bio (QTTB), Corvus Pharmaceuticals (CRVS), and Acelyrin (SLRN). These companies are all part of the "pharmaceutical products" industry. Actuate Therapeutics vs. Tectonic Therapeutic Neurogene AnaptysBio Exscientia Anavex Life Sciences CorMedix Nuvation Bio Q32 Bio Corvus Pharmaceuticals Acelyrin Actuate Therapeutics (NASDAQ:ACTU) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, community ranking, profitability, dividends and earnings. Do analysts rate ACTU or TECX? Tectonic Therapeutic has a consensus price target of $60.00, suggesting a potential upside of 46.77%. Given Tectonic Therapeutic's higher possible upside, analysts clearly believe Tectonic Therapeutic is more favorable than Actuate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ATectonic Therapeutic 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has stronger earnings & valuation, ACTU or TECX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActuate TherapeuticsN/AN/A-$24.75MN/AN/ATectonic TherapeuticN/AN/A$12.16M-$5.17-7.91 Is ACTU or TECX more profitable? Actuate Therapeutics' return on equity of 0.00% beat Tectonic Therapeutic's return on equity.Company Net Margins Return on Equity Return on Assets Actuate TherapeuticsN/A N/A N/A Tectonic Therapeutic N/A -41.05%-37.33% Does the MarketBeat Community favor ACTU or TECX? Tectonic Therapeutic received 4 more outperform votes than Actuate Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformActuate TherapeuticsN/AN/ATectonic TherapeuticOutperform Votes4100.00% Underperform VotesNo Votes Does the media prefer ACTU or TECX? In the previous week, Tectonic Therapeutic had 2 more articles in the media than Actuate Therapeutics. MarketBeat recorded 4 mentions for Tectonic Therapeutic and 2 mentions for Actuate Therapeutics. Tectonic Therapeutic's average media sentiment score of 0.67 beat Actuate Therapeutics' score of 0.22 indicating that Tectonic Therapeutic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actuate Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tectonic Therapeutic 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in ACTU or TECX? 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 9.2% of Tectonic Therapeutic shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryTectonic Therapeutic beats Actuate Therapeutics on 9 of the 11 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACTU vs. The Competition Export to ExcelMetricActuate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$156.63M$7.02B$5.33B$8.52BDividend YieldN/A7.92%5.07%4.13%P/E RatioN/A12.34128.5816.13Price / SalesN/A402.651,490.3793.20Price / CashN/A47.4339.6234.18Price / BookN/A5.604.765.07Net Income-$24.75M$153.56M$118.92M$225.46M7 Day Performance-5.87%0.13%0.78%0.54%1 Month Performance12.96%15.20%5.62%3.75%1 Year PerformanceN/A41.12%36.67%29.48% Actuate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACTUActuate TherapeuticsN/A$8.02-1.4%N/AN/A$156.63MN/A0.0010News CoverageGap UpHigh Trading VolumeTECXTectonic Therapeutic3.3111 of 5 stars$40.88-0.4%$60.00+46.8%N/A$602.16MN/A-7.91120Positive NewsGap UpHigh Trading VolumeNGNENeurogene1.8004 of 5 stars$46.07+4.7%$51.00+10.7%N/A$598.45MN/A0.0090ANABAnaptysBio3.0621 of 5 stars$21.68+0.2%$55.73+157.0%+31.1%$594.77M$30.47M-3.41100Upcoming EarningsAnalyst ForecastNews CoverageEXAIExscientia1.4408 of 5 stars$4.90+0.8%$7.00+42.9%-7.5%$592.36M$25.60M-3.77280Positive NewsAVXLAnavex Life Sciences3.4984 of 5 stars$6.84+3.2%$40.00+485.2%+21.6%$579.58MN/A-13.6740News CoverageCRMDCorMedix2.7105 of 5 stars$9.99-0.6%$15.20+52.2%+193.8%$577.02M$60,000.00-12.3330Earnings ReportAnalyst ForecastNews CoverageHigh Trading VolumeNUVBNuvation Bio3.8286 of 5 stars$2.30+4.1%$6.40+178.3%+98.3%$573.25MN/A-1.0960Upcoming EarningsQTTBQ32 Bio1.9784 of 5 stars$47.43+0.4%$72.33+52.5%N/A$572.01M$1.16M-2.0639News CoverageCRVSCorvus Pharmaceuticals1.5974 of 5 stars$9.10+2.9%$10.83+19.0%+671.2%$569.21MN/A-20.2230Upcoming EarningsAnalyst DowngradeShort Interest ↑SLRNAcelyrin3.1459 of 5 stars$5.62-1.1%$11.17+98.7%-38.4%$560.92MN/A-1.98135Upcoming Earnings Related Companies and Tools Related Companies TECX Competitors NGNE Competitors ANAB Competitors EXAI Competitors AVXL Competitors CRMD Competitors NUVB Competitors QTTB Competitors CRVS Competitors SLRN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACTU) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
